Quick Summary
BDR Pharmaceuticals is reportedly in talks to acquire Acme Formulation from private equity firm PAG in a deal valued between $200 million and $250 million. The acquisition would strengthen BDR’s CDMO business, expand its manufacturing capabilities, and enhance its global pharmaceutical footprint.
BDR Pharmaceuticals to Acquire Acme Formulation: Everything You Need to Know
India’s pharmaceutical industry could witness one of its biggest mergers in recent years as BDR Pharmaceuticals is reportedly planning to acquire Acme Formulation, a leading Contract Development and Manufacturing Organization (CDMO), from private equity firm PAG.
The proposed acquisition is expected to be valued between $200 million and $250 million. If completed, the deal will significantly strengthen BDR Pharmaceuticals’ manufacturing, research, and global export capabilities.
Overview
| Particular | Details |
|---|---|
| Company Acquiring | BDR Pharmaceuticals |
| Target Company | Acme Formulation |
| Current Owner | PAG |
| Expected Deal Value | $200–250 Million |
| Industry | Pharmaceutical CDMO |
| Deal Status | Reportedly Under Discussion |
What is the Proposed Acquisition?
According to industry reports, Mumbai-based BDR Pharmaceuticals is in advanced discussions to acquire PAG’s controlling stake in Acme Formulation.
PAG acquired a majority stake in Acme Formulation in 2021 for approximately $145 million (₹1,054 crore) through its PAG Asia III Buyout Fund.
If the transaction is finalized:
- BDR Pharmaceuticals will acquire PAG’s controlling stake.
- Founder Viral Shah is expected to retain his minority shareholding.
- Viral Shah is also expected to continue as Managing Director and CEO.
Several strategic buyers, including Akums Drugs & Pharmaceuticals, reportedly evaluated the acquisition opportunity.
About Acme Formulation
Established in 2005, Acme Formulation is headquartered in Himachal Pradesh and has become one of India’s leading pharmaceutical CDMO companies.
The company offers:
- Contract Development
- Contract Manufacturing
- Pharmaceutical R&D
- Product Development
- Regulatory Support
Its group companies include:
- Acme Formulation
- Immacule Lifesciences
- Acme Generics
- Veritas Research
Manufacturing Capabilities
Acme operates large-scale manufacturing facilities with more than 1 million square feet of production space.
Products Manufactured
- Tablets
- Capsules
- Sterile Injectables
- Oral Hormones
- Ophthalmic Products
- Vials
- Pre-filled Syringes
- Complex Formulations
Global Regulatory Approvals
Acme’s facilities comply with several international regulatory standards.
| Regulatory Authority | Status |
|---|---|
| US FDA | Approved |
| UK MHRA | Approved |
| EU GMP | Approved |
| Health Canada | Approved |
The company’s US generics business currently has:
- 38 Approved ANDAs
- 18 ANDAs Under Review
Global Presence
Acme exports pharmaceutical products to more than 40 countries.
Some of its major customers include:
- Abbott
- GSK
- Sandoz
- Biocon
- Merck
- Alkem
- Baxter
- Torrent Pharmaceuticals
- Cipla
- Emcure
- Mankind Pharma
- Dr. Reddy’s Laboratories
- Lupin
- Zydus
Financial Performance
Despite slightly lower revenue, Acme has improved its profitability through better operational efficiency.
| Financial Metric | FY24 | FY25 |
|---|---|---|
| Revenue | $71.3 Million | $68.3 Million |
| EBITDA | $11.9 Million | $14.6 Million |
| Net Profit | $6.4 Million | $8.5 Million |
Key Highlights
- EBITDA increased by 26%
- Net profit grew by 35%
- Five-year CAGR reached 45%
Why is BDR Pharmaceuticals Interested in Acquiring Acme?
The acquisition aligns with BDR Pharmaceuticals’ expansion strategy.
Key Benefits
- Stronger CDMO business
- Increased manufacturing capacity
- Better access to regulated global markets
- Enhanced pharmaceutical R&D
- Larger export footprint
- Expanded specialty medicine portfolio
Impact on the Indian Pharmaceutical Industry
If the acquisition is completed, it could:
- Strengthen India’s CDMO ecosystem.
- Increase pharmaceutical exports.
- Improve manufacturing capabilities.
- Encourage more private equity investments.
- Enhance India’s position as a global pharmaceutical manufacturing hub.
Key Facts at a Glance
| Particular | Information |
|---|---|
| Founded | 2005 |
| Headquarters | Himachal Pradesh |
| Employees | 2,500+ |
| Manufacturing Area | 1 Million+ sq. ft. |
| Export Countries | 40+ |
| Approved ANDAs | 38 |
| ANDAs Under Review | 18 |
Important Dates
| Event | Status |
|---|---|
| Acquisition Discussions | Ongoing |
| Official Completion Date | Not announced |
Important Links
| Resource | Status |
|---|---|
| Official BDR Pharmaceuticals Website | Refer to the official website |
| Official Company Announcement | Not yet released |
| Stock Exchange Filing | Not mentioned |
Why Should Pharmacy Students and Professionals Read This News?
Understanding major pharmaceutical acquisitions helps pharmacy students and professionals stay informed about industry trends.
This deal highlights:
- Growth of India’s CDMO sector
- Expansion of specialty pharmaceutical companies
- Increasing private equity investments
- Career opportunities in pharmaceutical manufacturing and research
- Future business trends in the Indian pharma industry
Conclusion
The proposed acquisition of Acme Formulation by BDR Pharmaceuticals represents a significant strategic move in India’s pharmaceutical sector. With Acme’s strong manufacturing infrastructure, global regulatory approvals, diversified customer base, and improving financial performance, the acquisition could substantially strengthen BDR’s position in the global CDMO market.
Although the transaction has not yet been officially confirmed, it reflects the increasing importance of contract manufacturing and pharmaceutical innovation in India’s rapidly growing healthcare ecosystem.
Frequently Asked Questions (FAQs)
1. Why is BDR Pharmaceuticals acquiring Acme Formulation?
BDR Pharmaceuticals aims to strengthen its CDMO business, manufacturing capacity, and international presence.
2. What is the expected value of the deal?
The acquisition is expected to be valued between $200 million and $250 million.
3. Who currently owns Acme Formulation?
Private equity firm PAG owns the controlling stake, while founder Viral Shah holds a significant minority stake.
4. What does Acme Formulation manufacture?
Acme manufactures tablets, capsules, sterile injectables, ophthalmic products, oral hormones, and complex pharmaceutical formulations.
5. Which global approvals does Acme have?
Its manufacturing facilities are approved by:
- US FDA
- UK MHRA
- EU GMP
- Health Canada
6. How many countries does Acme export to?
Acme exports pharmaceutical products to more than 40 countries worldwide.
7. Is the acquisition officially confirmed?
No. The discussions have been reported, but the companies have not officially announced the completion of the transaction.
8. Why is this acquisition important for India’s pharmaceutical industry?
The deal could strengthen India’s CDMO sector, boost exports, improve manufacturing capacity, and attract more investment into pharmaceutical research and production.
Recommended Products
